Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 15/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.73 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL414128 | 0.99 | ADORA1 (0.72) | ADORA1ADORA2AKDM1AADORA3ADORA2B | |
| SCHEMBL10135692 | 0.93 | ADORA1 (0.74) | ADORA1ADORA2AADORA3ADORA2B | |
| Hydrochloric Acid SCHEMBL414208 | 0.92 | ADORA1 (0.62) | ADORA1ADORA2AKDM1AADORA3ADORA2B | |
| SCHEMBL19720077 | 0.92 | ADORA1 (0.64) | ADORA1ADORA2AKDM1AADORA3ADORA2B | |
| SCHEMBL10136214 | 0.92 | ADORA1 (0.60) | ADORA1ADORA2AKDM1AADORA3ADORA2B | |
| SCHEMBL414307 | 0.91 | ADORA1 (0.75) | ADORA1ADORA2AADORA3ADORA2B | |
| Hydrochloric Acid SCHEMBL1740963 | 0.91 | ADORA1 (0.62) | ADORA1ADORA2AKDM1AADORA3ADORA2B | |
| SCHEMBL412422 | 0.91 | ADORA1 (0.74) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL415216 | 0.90 | ADORA1 (0.73) | ADORA1ADORA2AADORA3ADORA2B | |
| Hydrochloric Acid SCHEMBL948373 | 0.90 | ADORA1 (0.74) | ADORA1ADORA2AADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393552-B1 | A CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2017-12-20 | — | — | EP | claimed |
| US-9708292-B2 | Cyanopyrimidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-18 | — | — | US | claimed |
| US-20120022077-A1 | NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | claimed |
| EP-2393552-A1 | A NOVEL CYANOPYRIMIDINE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-12-14 | — | — | EP | claimed |
| WO-2010090299-A1 | A NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | claimed |
| EP-2393552-B1 | A CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| EP-2393552-B1 | A CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9708292-B2 | Cyanopyrimidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-9708292-B2 | Cyanopyrimidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20120022077-A1 | NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120022077-A1 | NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| EP-2393552-A1 | A NOVEL CYANOPYRIMIDINE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090299-A1 | A NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010090299-A1 | A NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022077-A1 | NOVEL CYANOPYRIMIDINE DERIVATIVE | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885KDM1A 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.